Quince Therapeutics Inc., a late-stage biotechnology company, has achieved a significant milestone in its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T), with over 75% enrollment. Additionally, Quince received FDA Fast Track designation for its eDSP System, designed to treat A-T patients. This designation, based on the potential of eDSP to address high unmet medical needs, facilitates expedited review processes, indicating promising advancements in Quince's efforts to combat this rare neurodegenerative disease. The company plans to submit a New Drug Application to the FDA in the second half of 2026, assuming positive study outcomes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。